We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+51.8%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$24.1M
Cap. Flow
-$43.1M
Cap. Flow %
-11.96%
Top 10 Hldgs %
41.39%
Holding
100
New
33
Increased
9
Reduced
32
Closed
23

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$11.1M
2
RNAM
Avidity Biosciences
RNAM
+$7.67M
3
CATX icon
Perspective Therapeutics
CATX
+$6.91M
4
SLDB icon
Solid Biosciences
SLDB
+$6.83M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$6.54M

Top Sells

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$13.7M
2
MGNX icon
MacroGenics
MGNX
+$11.8M
3
MDT icon
Medtronic
MDT
+$11.1M
4
SNY icon
Sanofi
SNY
+$10.9M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
26
EyePoint Inc
EYPT
$1.08B
$5.13M 1.42%
+247,968
New +$6.14M
BOLD
27
Boundless Bio
BOLD
$56.2M
$4.45M 1.24%
+312,500
New +$4.45M
TELA icon
28
TELA Bio
TELA
$31.8M
$4.4M 1.22%
776,851
-18,229
-2% -$120K
BIIB icon
29
Biogen
BIIB
$30.7B
$4.18M 1.16%
19,365
-635
-3% -$149K
FULC icon
30
Fulcrum Therapeutics
FULC
$248M
$3.76M 1.04%
+398,436
New +$3.56M
SRRK icon
31
Scholar Rock
SRRK
$5.87B
$3.54M 0.98%
199,415
-70,585
-26% -$1.11M
CYTK icon
32
Cytokinetics
CYTK
$10.9B
$3.51M 0.97%
+50,000
New +$3.87M
APGE icon
33
Apogee Therapeutics
APGE
$10.2B
$3.32M 0.92%
+50,000
New +$2.18M
JSPR icon
34
Jasper Therapeutics
JSPR
$20.7M
$3.23M 0.9%
+109,892
New +$1.95M
INSM icon
35
Insmed
INSM
$22B
$3.08M 0.86%
113,616
-41,888
-27% -$1.17M
WVE icon
36
Wave Life Sciences
WVE
$1.11B
$3.06M 0.85%
+495,471
New +$2.48M
TRVI icon
37
Trevi Therapeutics
TRVI
$2.61B
$2.91M 0.81%
844,235
-19,648
-2% -$43.8K
XENE icon
38
Xenon Pharmaceuticals
XENE
$6.2B
$2.85M 0.79%
66,090
-97,078
-59% -$4.47M
DXCM icon
39
DexCom
DXCM
$28.8B
$2.77M 0.77%
20,000
-11,000
-35% -$1.38M
CERS icon
40
Cerus
CERS
$579M
$2.77M 0.77%
1,465,744
-34,107
-2% -$69.5K
PLRX icon
41
Pliant Therapeutics
PLRX
$65.6M
$2.73M 0.76%
183,392
-135,132
-42% -$2.23M
RCKT icon
42
Rocket Pharmaceuticals
RCKT
$351M
$2.72M 0.76%
101,002
-281,670
-74% -$8M
CGEN icon
43
Compugen
CGEN
$220M
$2.58M 0.72%
1,000,000
+60,000
+6% +$140K
ITCI
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.41M 0.67%
34,807
-45,193
-56% -$3.11M
NAMS icon
45
NewAmsterdam Pharma
NAMS
$3.33B
$2.36M 0.65%
+99,612
New +$2.02M
EVGN icon
46
Evogene
EVGN
$5.92M
$2.31M 0.64%
308,550
-1,450
-0.5% -$12.1K
ADCT icon
47
ADC Therapeutics
ADCT
$141M
$2.25M 0.63%
+501,222
New +$1.85M
VRNA
48
DELISTED
Verona Pharma
VRNA
$2.2M 0.61%
+136,714
New +$2.36M
MGNX icon
49
CALL
MacroGenics
MGNX
$240M
$2.14M 0.59%
+145,500
New +$2.2M
MIRM icon
50
Mirum Pharmaceuticals
MIRM
$6.87B
$1.99M 0.55%
79,194
-1,617
-2% -$44.5K
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Silverarc Capital Management held 100 positions worth $360M, up 7.2% from $336M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Silverarc Capital Management withdrew a net $43.1M in Q1 2024, closing 23 positions and reducing 32 holdings. Its most notable exit was Medtronic, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in C4 Therapeutics worth $11.7M.

  • Silverarc Capital Management's largest Q1 2024 buy was C4 Therapeutics: 1,435,931 shares worth $11.7M.
  • Silverarc Capital Management added most to Solid Biosciences in Q1 2024, an estimated $6.83M increase.
  • Silverarc Capital Management's biggest Q1 2024 reduction was Mersana Therapeutics, cutting an estimated $13.7M.
  • Silverarc Capital Management fully exited Medtronic in Q1 2024, selling an estimated $11.1M.
  • Silverarc Capital Management's ten largest holdings make up 41% of its $360M portfolio in Q1 2024.
  • Silverarc Capital Management opened 33 new positions and closed 23 in Q1 2024.
  • Silverarc Capital Management's portfolio value rose 7.2% quarter-over-quarter to $360M.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.